Published in Liver Transpl on March 01, 2002
ALPPS offers a better chance of complete resection in patients with primarily unresectable liver tumors compared with conventional-staged hepatectomies: results of a multicenter analysis. World J Surg (2014) 3.60
Preoperative portal vein embolization for extended hepatectomy. Ann Surg (2003) 2.33
Liver planning software accurately predicts postoperative liver volume and measures early regeneration. J Am Coll Surg (2014) 2.19
Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg (2004) 2.01
Assessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resection. J Gastrointest Surg (2010) 1.81
Portal vein embolization before liver resection: a systematic review. Cardiovasc Intervent Radiol (2012) 1.50
Definition of Readmission in 3,041 Patients Undergoing Hepatectomy. J Am Coll Surg (2015) 1.48
Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg (2012) 1.17
Estimating liver weight of adults by body weight and gender. World J Gastroenterol (2006) 1.17
Portal vein thrombosis is a potentially preventable complication in clinical islet transplantation. Am J Transplant (2011) 1.10
Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol (2013) 1.05
New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointest Cancer Res (2007) 1.03
Liver involvement in early autosomal-dominant polycystic kidney disease. Clin Gastroenterol Hepatol (2014) 1.03
Standardized liver volumetry for portal vein embolization. Semin Intervent Radiol (2008) 1.01
Comparison of proposed alternative methods for rescaling dialysis dose: resting energy expenditure, high metabolic rate organ mass, liver size, and body surface area. Semin Dial (2008) 1.00
Liver and spleen volume variations in patients with hepatic fibrosis. World J Gastroenterol (2009) 0.96
Surgical resection of high-risk hepatocellular carcinoma: patient selection, preoperative considerations, and operative technique. Ann Surg Oncol (2010) 0.95
Comparison of techniques for volumetric analysis of the future liver remnant: implications for major hepatic resections. HPB (Oxford) (2015) 0.93
Pediatric liver transplantation. World J Gastroenterol (2009) 0.92
Is the liver kinetic growth rate in ALPPS unprecedented when compared with PVE and living donor liver transplant? A multicentre analysis. HPB (Oxford) (2015) 0.92
Remnant growth rate after portal vein embolization is a good early predictor of post-hepatectomy liver failure. J Am Coll Surg (2014) 0.91
Comparison of four embolic materials for portal vein embolization: experimental study in pigs. Eur Radiol (2009) 0.91
Liver function following extended hepatectomy can be accurately predicted using remnant liver volume to body weight ratio. World J Surg (2015) 0.90
Portal vein embolization for hepatocellular carcinoma. Liver Cancer (2012) 0.90
Small for size liver remnant following resection: prevention and management. Hepatobiliary Surg Nutr (2014) 0.87
Patient Survival After Simultaneous ALPPS and Colorectal Resection. World J Surg (2016) 0.85
Uses and limitations of portal vein embolization for improving perioperative outcomes in hepatocellular carcinoma. Semin Oncol (2010) 0.84
Evaluation of standard liver volume formulae for Chinese adults. World J Gastroenterol (2009) 0.83
Liver/spleen volume ratio as a predictor of prognosis in primary biliary cirrhosis. J Gastroenterol (2008) 0.83
Portal vein embolization: rationale, technique, and current application. Semin Intervent Radiol (2012) 0.82
Volumetric analysis and indocyanine green retention rate at 15 min as predictors of post-hepatectomy liver failure. HPB (Oxford) (2014) 0.82
Impact of estimated liver volume and liver weight on gender disparity in liver transplantation. Liver Transpl (2012) 0.81
Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol (2012) 0.80
Limiting factors for liver regeneration after a major hepatic resection for colorectal cancer metastases. HPB (Oxford) (2013) 0.80
Percutaneous transhepatic portal vein embolization: rationale, technique, and outcomes. Semin Intervent Radiol (2008) 0.80
Identification of cofactors influencing hypertrophy of the future liver remnant after portal vein embolization-the effect of collaterals on embolized liver volume. Br J Radiol (2016) 0.80
Donor safety and remnant liver volume in living donor liver transplantation. World J Gastroenterol (2012) 0.79
Are two-stage hepatectomies associated with more complications than one-stage procedures? HPB (Oxford) (2012) 0.79
Historical perspective of living donor liver transplantation. World J Gastroenterol (2008) 0.79
Is computed tomography volumetric assessment of the liver reliable in patients with cirrhosis? HPB (Oxford) (2013) 0.79
Small liver remnants are more vulnerable to ischemia/reperfusion injury after extended hepatectomies: a case-control study. World J Surg (2012) 0.79
Accuracy of preoperative automatic measurement of the liver volume by CT-scan combined to a 3D virtual surgical planning software (3DVSP). Surg Endosc (2014) 0.78
Safety and efficacy of preoperative right portal vein embolization in patients at risk for postoperative liver failure following major right hepatectomy. HPB (Oxford) (2011) 0.78
Sizes of abdominal organs in adults with severe short stature due to severe, untreated, congenital GH deficiency caused by a homozygous mutation in the GHRH receptor gene. Clin Endocrinol (Oxf) (2008) 0.78
Increase in the serum bile acid level predicts the effective hypertrophy of the nonembolized hepatic lobe after right portal vein embolization. World J Surg (2009) 0.78
Indications, limitations and maneuvers to enable extended hepatectomy: current trends. World J Gastroenterol (2014) 0.78
Characterization of a porcine model for associating liver partition and portal vein ligation for a staged hepatectomy. HPB (Oxford) (2015) 0.78
Gd-EOB-DTPA-enhanced MRI for monitoring future liver remnant function after portal vein embolization and extended hemihepatectomy: A prospective trial. Eur Radiol (2016) 0.77
Comparison of remnant to total functional liver volume ratio and remnant to standard liver volume ratio as a predictor of postoperative liver function after liver resection. Korean J Hepatobiliary Pancreat Surg (2013) 0.77
Assessment of the optimal temporal window for intravenous CT cholangiography. Eur Radiol (2007) 0.77
Gastric emptying scintigraphy results in children are affected by age, anthropometric factors, and study duration. Neurogastroenterol Motil (2015) 0.77
Liver angulometry: a simple method to estimate liver volume and ratios. HPB (Oxford) (2013) 0.76
Hepatic height on coronal computed tomography images predicts total liver volume in European adults without liver disease. Dig Dis Sci (2012) 0.76
Measurement of liver function using hepatobiliary scintigraphy improves risk assessment in patients undergoing major liver resection. HPB (Oxford) (2016) 0.75
Transplantation: Liver steatosis and errors in estimation of standard liver volume. Nat Rev Gastroenterol Hepatol (2011) 0.75
Portal Vein Embolization as an Oncosurgical Strategy Prior to Major Hepatic Resection: Anatomic, Surgical, and Technical Considerations. Front Surg (2016) 0.75
Importance of primary indication and liver function between stages: results of a multicenter Italian audit of ALPPS 2012-2014. HPB (Oxford) (2016) 0.75
Portal vein embolization for induction of selective hepatic hypertrophy prior to major hepatectomy: rationale, techniques, outcomes and future directions. Cancer Biol Med (2016) 0.75
Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration. J Hepatocell Carcinoma (2016) 0.75
Risk of venous congestion in live donors of extended right liver graft. World J Gastroenterol (2015) 0.75
Body surface area formulae: an alarming ambiguity. Sci Rep (2016) 0.75
Calculation of standard liver volume in Korean adults with analysis of confounding variables. Korean J Hepatobiliary Pancreat Surg (2015) 0.75
New formula for predicting standard liver volume in Chinese adults. World J Gastroenterol (2017) 0.75
Anthropometric characterization of the child liver. Surg Radiol Anat (2010) 0.75
An assessment of the accuracy of hepatic and splenic size based upon a clinician's physical examination, a radiologist's impression and the actual liver and spleen volumes calculated by CT scanning. Dig Dis Sci (2008) 0.75
Portal vein embolization in extended liver resection. Langenbecks Arch Surg (2017) 0.75
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol (2008) 15.05
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood (2008) 6.39
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg (2005) 4.86
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol (2009) 4.82
We should desist using RECIST, at least in GIST. J Clin Oncol (2007) 4.51
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol (2008) 4.37
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther (2011) 4.22
Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg (2007) 4.09
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol (2005) 4.06
Steps toward mapping the human vasculature by phage display. Nat Med (2002) 3.82
Simplified staging for hepatocellular carcinoma. J Clin Oncol (2002) 3.48
Comparison of CT methods for determining the fat content of the liver. AJR Am J Roentgenol (2007) 3.45
Propensity matched analysis of bilateral internal mammary artery versus single left internal mammary artery grafting at 17-year follow-up: validation of a contemporary surgical experience. Eur J Cardiothorac Surg (2012) 3.41
CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol (2004) 3.38
Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg (2008) 3.36
Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol (2002) 3.32
Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol (2009) 3.22
Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg (2003) 3.16
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol (2004) 3.02
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood (2007) 2.91
Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res (2010) 2.82
Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest (2008) 2.73
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res (2011) 2.64
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant (2011) 2.63
Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg (2004) 2.62
Treatment of periodontal disease during pregnancy: a randomized controlled trial. Obstet Gynecol (2009) 2.62
Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg (2007) 2.62
Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int (2013) 2.53
Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol (2008) 2.52
Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg (2009) 2.44
Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl (2005) 2.43
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst (2008) 2.37
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst (2009) 2.34
High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol (2011) 2.28
Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol (2009) 2.27
Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol (2007) 2.26
Right portal vein ligation: a new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases. J Am Coll Surg (2003) 2.20
Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol (2012) 2.15
Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res (2005) 2.14
Extraosseous osteosarcoma: response to treatment and long-term outcome. J Clin Oncol (2002) 2.13
Semi-quantification of pneumothorax volume by lung ultrasound. Intensive Care Med (2014) 2.12
Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer (2007) 2.12
Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl (2013) 2.09
Standard-length catheters vs long catheters in ultrasound-guided peripheral vein cannulation. Am J Emerg Med (2011) 2.06
Solitary colorectal liver metastasis: resection determines outcome. Arch Surg (2006) 2.06
Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer (2010) 2.04
Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg (2003) 2.03
Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer (2002) 2.03
The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell (2012) 2.02
Biophysical profile with amniotic fluid volume assessments. Obstet Gynecol (2004) 2.01
Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg (2004) 2.01
Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl (2003) 2.01
Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg (2004) 1.99
Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg (2013) 1.98
3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet (2006) 1.97
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant (2008) 1.96
Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol (2011) 1.96
Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood (2014) 1.95
Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology (2013) 1.93
Splenic arterial interventions: anatomy, indications, technical considerations, and potential complications. Radiographics (2005) 1.85
Pancreaticoduodenectomy after placement of endobiliary metal stents. J Gastrointest Surg (2005) 1.84
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res (2012) 1.83
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer (2007) 1.83
The development and characterization of a human midgut carcinoid cell line. Clin Cancer Res (2007) 1.80
Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg (2004) 1.79
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol (2002) 1.79
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma (2014) 1.77
High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation (2009) 1.76
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood (2011) 1.75
A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med (2011) 1.74
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant (2002) 1.71
Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol (2006) 1.70
ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol (2009) 1.70
A strategy for ZnO nanorod mediated multi-mode cancer treatment. Biomaterials (2010) 1.70
Volume and frequency of breastfeedings and fat content of breast milk throughout the day. Pediatrics (2006) 1.69
Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 1.67
Protective importance of the myogenic response in the renal circulation. Hypertension (2009) 1.67
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol (2006) 1.67
Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res (2008) 1.64
Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology (2011) 1.64
A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol (2008) 1.64
Synchronous selection of homing peptides for multiple tissues by in vivo phage display. FASEB J (2006) 1.63
Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology (2009) 1.62
Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood (2011) 1.61
Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg (2010) 1.60
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59